(0.03%) 5 333.50 points
(0.02%) 39 952 points
(-0.05%) 18 754 points
(-1.69%) $78.45
(1.42%) $2.79
(-0.64%) $2 422.80
(-1.75%) $31.86
(-1.33%) $1 049.60
(-0.06%) $0.920
(-0.34%) $10.66
(-0.08%) $0.786
(-0.24%) $90.46
Quarter results today
(bmo 2024-05-21)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions...
Stats | |
---|---|
本日の出来高 | 3 777.00 |
平均出来高 | 28 237.00 |
時価総額 | 32.60M |
EPS | $0 ( 2024-05-08 ) |
次の収益日 | ( $0 ) 2024-06-25 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.300 |
ATR14 | $0.181 (2.99%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-23 | Franco-yehuda Chen | Buy | 355 000 | Common Stock |
2024-01-23 | Aberman Zami | Buy | 44 100 | Common Stock |
2024-01-23 | Birger Pinhas Doron | Buy | 39 900 | Common Stock |
2024-01-23 | Shemesh-rasmussen Maital | Buy | 38 150 | Common Stock |
2024-01-23 | Yanay Yaky | Buy | 700 000 | Common Stock |
INSIDER POWER |
---|
99.92 |
Last 95 transactions |
Buy: 8 548 074 | Sell: 1 004 814 |
Pluri Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Pluri Inc. 財務諸表
Annual | 2023 |
収益: | $287 000 |
総利益: | $278 000 (96.86 %) |
EPS: | $-6.18 |
FY | 2023 |
収益: | $287 000 |
総利益: | $278 000 (96.86 %) |
EPS: | $-6.18 |
FY | 2022 |
収益: | $234 000 |
総利益: | $-41.36M (-17 674.79 %) |
EPS: | $-1.270 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.770 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Pluri Inc.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。